Feb 18, 2021
Oncopeptides AB: Year-end Report 2020
Dec 21, 2020
Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma
Dec 15, 2020
Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations
Dec 09, 2020
Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology
Dec 06, 2020
Oncopeptides presents new data from phase 2 ANCHOR combination study in multiple myeloma at American Society of Hematology meeting ASH
Dec 04, 2020
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)
Nov 05, 2020
Oncopeptides hosts a virtual capital markets day on November 30
Nov 04, 2020
Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting
Oct 14, 2020
Oncopeptides signs EUR 40 million loan agreement with the EIB
Oct 01, 2020
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
Sep 08, 2020
Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit
Aug 29, 2020
FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
Aug 26, 2020
Oncopeptides AB: Interim Report Q2 2020
Aug 07, 2020
Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
Jul 31, 2020
Number of shares and votes in Oncopeptides
Jun 30, 2020
Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients
Jun 30, 2020
Number of Shares and Votes in Oncopeptides
Jun 30, 2020
Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO
Jun 29, 2020
Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021